Early-stage oncology startup Boundless Bio files for IPO
06 Mar 2024
IPOAcquisition
Boundless Bio has filed to go public as it approaches early safety and efficacy data for its first clinical attempt at a unique take on treating cancer.
The five-year-old San Diego startup
revealed its plans
Wednesday to trade on the Nasdaq as “BOLD.” The move comes as investor sentiment picks up with a flurry of follow-on offerings and
renewed interest in crossover rounds
.
Boundless, one of the many startups in ARCH Venture Partners’ sprawling portfolio, had previously raised about $250 million on the private side, including a
$100 million Series C
last May, shortly before it brought on ex-EQRx finance chief
Jami Rubin
to run finances.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.